Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Precision Biosciences Inc (DTIL) COM USD0.000005

Sell:$5.44 Buy:$5.45 Change: $0.47 (7.94%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Change: $0.47 (7.94%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Change: $0.47 (7.94%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Precision BioSciences, Inc. is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s four product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, PBCAR269A and PBCAR371A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.

Contact details

302 E Pettigrew St Ste A100
United States
+1 (919) 3145512

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$309.88 million
Shares in issue:
52.34 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Matthew Kane
    President, Chief Executive Officer, Director
  • Abid Ansari
    Chief Financial Officer
  • Fayaz Khazi
    Chief Executive Officer, Elo Life Systems
  • David Thomson
    Chief Operating Officer
  • Derek Jantz
    Chief Scientific Officer, Director
  • Dario Scimeca
    General Counsel, Secretary
  • Christopher Heery
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.